Putting the award page together from the records…
Putting the award page together from the records…
VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.
Up for re-bid: ends 2027-12-31. Recompete brief → · J&A to extend Period or Performance for procurement of Inmazeb ↗
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
10 actions since 2023-09-15. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-08-04 | P00009 | Funding only | $5.43M | THE PURPOSE OF THIS MODIFICATION IS TO: 1. PROVIDE SUPPLEMENTAL FUNDING FOR CLIN0001 2. EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 (BASE) THROUGH DECEMBER 31, 2029 3. ADD ACTIVITIES UNDER CLIN0002 AT NO ADDITIONAL COST TO THE GOVERNMENT 4. REV |
| 2026-05-27 | P00008 | Option exercised | $13.31M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN0002/OPTION 1, UPDATE THE PERIOD OF PERFORMANCE FOR CLIN0001/BASE THROUGH DECEMBER 31, 2027, AND SECTION J-ATTACHMENT 1 STATEMENT OF WORK DATED 3/26/2026. |
| 2026-02-24 | P00007 | Option exercised | $6.13M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN0005/OPTION 4, UPDATE ARTICLES G.3 KEY PERSONNEL, G.4.G CONTRACT FINANCIAL REPORT, G.8 POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE, CPARS POINT OF CONTACT, AND SECTION J, ATTACHMENT 1 STATEMENT |
| 2025-09-24 | P00006 | Novation (new contractor name or owner) | $0 | THE PURPOSE OF THIS MODIFICATION IS TO FINALIZE THE NOVATION AGREEMENT VIA THIS MODIFICATION THE UNITED STATES GOVERNMENT RECOGNIZES THAT ALL CONTRACTUAL OBLIGATIONS HAVE BEEN TRANSFERRED FROM VENATORX PHARMACEUTICALS, INC. TO BASILEA PHARMACEUTICA I |
| 2025-05-07 | P00005 | Administrative change | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO UPDATE ARTICLE G.7 INDIRECT COST RATES BASED ON DOCUMENTATION FROM NIH DATED APRIL 23, 2025, AND ARTICLE I.1 FAR 52.252-52, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998) IN ACCORDANCE WITH (I) FAR CL |
| 2024-11-25 | P00004 | Administrative change | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLES I.1 FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES, 52.204-14 SERVICES CONTRACT REPORTING REQUIREMENTS. |
| 2024-06-28 | P00003 | Administrative change | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE G.1 CONTRACTING OFFICER, ARTICLE G.3 KEY PERSONNEL, AND UPDATE ATTACHMENT #1 - STATEMENT OF WORK DATED APRIL 25, 2024, BY REALIGNING WORK TO CORRESPONDING MILESTONES AT NO ADDITIONAL COST TO THE G |
| 2024-01-31 | P00002 | Administrative change | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE G.7 INDIRECT COST RATE |
| 2023-11-20 | P00001 | Administrative change | $0 | NO COST MODIFICATION TO UPDATE SECTION G.3 KEY PERONNEL |
| 2023-09-15 | 0 | $20.32M | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-20). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗